Status:
COMPLETED
Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.
Lead Sponsor:
University Hospital, Antwerp
Collaborating Sponsors:
Universiteit Antwerpen
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study to evaluate the feasibility of the implementation of a personalized treatment strategy based on specific tumor marker (f.i. EGFR-mutation) in the routine clinical care s...
Detailed Description
The favourable results of a number of phase III-trials with gefitinib in NSCLC patients with activating EGFR-mutations, have resulted in the licensing of gefitinib in this indication. This offers the ...
Eligibility Criteria
Inclusion
- age 18 years or above
- newly diagnosed NSCLC
- written informed consent
- tumor sample available
Exclusion
- mixed histology of small cell and NSCLC
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT01260038
Start Date
November 1 2010
End Date
September 1 2011
Last Update
January 18 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, Belgium, 2650
2
AZ Monica
Antwerp, Belgium
3
GZA Sint Vincentius - Sint Augustinus
Antwerp, Belgium
4
ZNA Middelheim - ZNA STER - ZNA Jan Palfijn
Antwerp, Belgium